Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Total Current Liabilities came in at $46.4 million in Q1 2026, up 1.08% YoY from $45.9 million in Q1 2025, and up 3.83% on a QoQ basis from $44.7 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Total Current Liabilities data on file, last reported at $46.4 million in Q1 2026.
- Quarterly Total Current Liabilities rose 1.08% year-over-year to $46.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $46.4 million (up 1.08% YoY) and the FY2025 annual result came in at $48.6 million, down 15.61% from the prior year.
- Total Current Liabilities rose to $46.4 million in Q1 2026, from $44.7 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $68.2 million in Q2 2023 to a low of $23.0 million in Q4 2022.
- A 5-year average of $46.0 million and a median of $46.4 million in 2026 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities slumped 39.3% — and 2023, when it soared 196.02%.
- Tracing ENTA's Total Current Liabilities over 5 years: stood at $23.0 million in 2022, then jumped by 171.32% to $62.4 million in 2023, then dropped by 21.4% to $49.0 million in 2024, then dropped by 8.81% to $44.7 million in 2025, then grew by 3.83% to $46.4 million in 2026.
- The last three Total Current Liabilities figures came in at $46.4 million (Q1 2026), $44.7 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 54.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.17 Mn |
| Mar 31, 2026 | 46.44 Mn |
| Dec 31, 2025 | 44.73 Mn |
| Sep 30, 2025 | 48.56 Mn |
| Jun 30, 2025 | 44.55 Mn |
| Mar 31, 2025 | 45.95 Mn |
| Dec 31, 2024 | 49.05 Mn |
| Sep 30, 2024 | 57.54 Mn |
| Jun 30, 2024 | 58.23 Mn |
| Mar 31, 2024 | 54.61 Mn |
| Dec 31, 2023 | 62.41 Mn |
| Sep 30, 2023 | 62.79 Mn |
| Jun 30, 2023 | 68.19 Mn |
| Mar 31, 2023 | 32.17 Mn |
| Dec 31, 2022 | 23.00 Mn |
| Sep 30, 2022 | 29.83 Mn |
| Jun 30, 2022 | 23.04 Mn |
| Mar 31, 2022 | 30.74 Mn |
| Dec 31, 2021 | 37.89 Mn |
| Sep 30, 2021 | 36.17 Mn |